Yahoo
NasdaqGM - Delayed Quote USD

Drugs Made In America Acquisition II Corp. (DMII)

10.21 -0.01 (-0.10%)
At close: November 6 at 4:00:00 PM EST
Trade DMII on Coinbase
Chart Range Bar
Loading chart for DMII
  • Previous Close 10.22
  • Open 10.21
  • Bid 10.11 x 100
  • Ask 10.09 x 200
  • Day's Range 10.21 - 10.21
  • 52 Week Range 9.86 - 10.33
  • Volume 70,125
  • Avg. Volume 111,928
  • Market Cap (intraday) 650.377M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 34.03
  • EPS (TTM) 0.30
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.

--

Full Time Employees

December 31

Fiscal Year Ends

Shell Companies

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DMII
3.13%
S&P 500 (^GSPC)
7.76%

1-Year Return

DMII
3.44%
S&P 500 (^GSPC)
9.77%

3-Year Return

DMII
3.44%
S&P 500 (^GSPC)
68.96%

5-Year Return

DMII
3.44%
S&P 500 (^GSPC)
57.04%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    13.02M

  • Diluted EPS (ttm)

    0.30

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    174.97k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: